Peter Lynch was known for finding HIDDEN GEMS IN THE MARKET before they became mainstream. Is UNITED THERAPEUTICS CORP (NASDAQ:UTHR [https://www.chartmill.com/stock/quote/UTHR/profile]) one of those under-the-radar stocks that fits his legendary strategy?

[Growth stocks image]

DOES UNITED THERAPEUTICS CORP (NASDAQ:UTHR) MEET PETER LYNCH’S STOCK-PICKING CRITERIA?

 	* With a favorable Return on Equity (ROE) of 18.55%, UTHR demonstrates its ability to deliver attractive returns for shareholders. This metric highlights the company's EFFECTIVE MANAGEMENT OF ASSETS AND ITS PROFITABILITY.
 	* A Debt/Equity ratio of 0.0 suggests that UTHR is MANAGING ITS DEBT LEVELS RESPONSIBLY.
 	* The 5-year EPS growth of UTHR (16.88) highlights the company's ability to CONSISTENTLY IMPROVE ITS EARNINGS PERFORMANCE and suggests a positive outlook for future profitability.
 	* A PEG ratio of 0.7 positions UTHR as a WELL-VALUED GROWTH STOCK in today’s market.
 	* With a Current Ratio of 5.25, UTHR appears well-positioned to MEET ITS NEAR-TERM FINANCIAL OBLIGATIONS.

WHAT IS THE FULL FUNDAMENTAL PICTURE OF UTHR TELLING US.

ChartMill assigns a proprietary FUNDAMENTAL RATING to each stock. The score is computed daily by evaluating various fundamental indicators and properties. The score ranges from 0 to 10.

Overall UTHR gets a fundamental rating of 7 out of 10. We evaluated UTHR against 563 industry peers in the BIOTECHNOLOGY industry. Both the health and profitability get an excellent rating, making UTHR a very profitable company, without any liquidiy or solvency issues. UTHR scores decently on growth, while it is valued quite cheap. This could make an interesting combination. This makes UTHR very considerable for value and quality investing!

Check the latest full fundamental report of UTHR [https://www.chartmill.com/stock/quote/UTHR/fundamental-analysis] for a complete fundamental analysis.

Every day, new Affordable Growth stocks can be found on ChartMill in our Peter Lynch screener [https://www.chartmill.com/stock/stock-screener?sid=685&f=sl_eps5y_15_30,sl_roe_15_X,sl_peg5_X_1,sl_cr_1_X,sl_deq_X_0.6,v1_50b100&v=19&s=fa&sd=DESC&cpl=2&bc=false&nw=1&o1=3&op1=200,16711680&o2=3&op2=50,255&o3=1].

DISCLAIMER

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.